JPH05163142A - Arachidonic acid-containing composition for preventing and treating liver disease - Google Patents
Arachidonic acid-containing composition for preventing and treating liver diseaseInfo
- Publication number
- JPH05163142A JPH05163142A JP33326791A JP33326791A JPH05163142A JP H05163142 A JPH05163142 A JP H05163142A JP 33326791 A JP33326791 A JP 33326791A JP 33326791 A JP33326791 A JP 33326791A JP H05163142 A JPH05163142 A JP H05163142A
- Authority
- JP
- Japan
- Prior art keywords
- arachidonic acid
- preventing
- acid
- containing composition
- treating liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、必須成分として、比較
的多量のアラキドン酸を含有する油脂を配合した、肝障
害の予防または治療用の食品や医薬、動物用飼料等とし
て有用なアラキドン酸含有組成物に関する。FIELD OF THE INVENTION The present invention relates to arachidonic acid useful as a food, medicine, animal feed, etc. for preventing or treating liver damage, which contains an oil and fat containing a relatively large amount of arachidonic acid as an essential component. Containing composition.
【０００２】[0002]
【従来の技術】非代償性肝硬変では、血漿多価不飽和脂
肪酸濃度の著名な低下が認められており、その原因とし
て、脂質の摂取不足と肝における合成障害が推定され
る。例えば、脂質の摂取量につき健常例と肝硬変例にお
いて比較すると、特に、アラキドン酸の摂取量が肝硬変
においてかなり不足していることが判明している。一
方、従来から、アラキドン酸はプロスタグランジン類や
ロイコトリエン類の生物学的前駆体であることが知られ
ており、生体内では、アラキドン酸はリノール酸から、
γ−リノレン酸を経て合成され、合成されたアラキドン
酸がプロスタグランジンに変換され、これが肝障害の予
防、治療に効果を発揮すると考えられている。したがっ
て、肝障害の予防および治療のために、リノール酸や、
アラキドン酸を投与することが有効と考えられ、特開昭
５９−６２５２２号においては、リノール酸やアラキド
ン酸を界面活性剤と共に水溶性の組成物として経口投与
し、肝障害の予防や治療に用いることが提案されてい
る。しかし、リノール酸を用いる場合はともかく、アラ
キドン酸を用いた実用的な肝障害の予防または治療剤は
未だ見当らない。すなわち、リノール酸は通常の油脂食
品中に多量に含有されており、その入手は容易で、食物
としての摂取によって所望の効果を期待できるものの、
アラキドン酸は油脂食品等に少量含有されているにすぎ
ず、肝障害の予防や治療に十分な量を安価に入手するこ
とは困難である。事実、特開昭５９−６２５２２号にお
いてはアラキドン酸は高価な精製遊離脂肪酸の形態で使
用されており、実用的でない。しかも、非代償性肝硬変
ではリノール酸からの合成過程に必要な酵素が阻害され
るため、リノール酸からのアラキドン酸の合成が進ま
ず、直接アラキドン酸を投与することが必要となる。2. Description of the Related Art In decompensated cirrhosis, a marked decrease in plasma polyunsaturated fatty acid concentration has been recognized, which is presumed to be due to insufficient lipid intake and hepatic synthetic disorder. For example, comparing lipid intakes in healthy and cirrhotic cases, it has been found that the intake of arachidonic acid is particularly insufficient in cirrhosis. On the other hand, conventionally, arachidonic acid is known to be a biological precursor of prostaglandins and leukotrienes, and in vivo, arachidonic acid is derived from linoleic acid.
It is considered that arachidonic acid synthesized through γ-linolenic acid is converted into prostaglandin, which is effective in preventing and treating liver damage. Therefore, for the prevention and treatment of liver damage, linoleic acid,
It is considered effective to administer arachidonic acid, and in JP-A-59-62522, linoleic acid and arachidonic acid are orally administered together with a surfactant as a water-soluble composition and used for the prevention and treatment of liver damage. Is proposed. However, regardless of the case of using linoleic acid, a practical prophylactic or therapeutic agent for liver damage using arachidonic acid has not been found yet. That is, linoleic acid is contained in a large amount in ordinary oil and fat foods, and it is easily available, and although a desired effect can be expected by ingestion as food,
Arachidonic acid is contained only in a small amount in oil and fat foods, etc., and it is difficult to inexpensively obtain a sufficient amount for preventing or treating liver damage. In fact, in JP-A-59-62522, arachidonic acid is used in the form of expensive purified free fatty acid, which is not practical. Moreover, in decompensated cirrhosis, the enzyme required for the synthesis process from linoleic acid is inhibited, so that the synthesis of arachidonic acid from linoleic acid does not proceed and it is necessary to directly administer arachidonic acid.
【０００３】[0003]
【発明が解決しようとする課題】このような事情に鑑
み、本発明者らはアラキドン酸を用いた実用的な肝障害
の予防または治療剤を得るべく鋭意研究を行った結果、
例えば、特開昭６３−４４８９１号等に開示されるよう
な微生物学的方法により得られる高濃度のアラキドン酸
を含有する油脂がその目的に好適であり、そのような油
脂を配合した組成物が、エタノール、薬剤等により障害
を起こした肝臓においてプロスタグランジン量を増加さ
せ、肝障害の予防および治療に有用であることを見いだ
し、本発明を完成するに至った。In view of such circumstances, the present inventors have conducted diligent research to obtain a practical prophylactic or therapeutic agent for hepatic disorder using arachidonic acid, and as a result,
For example, oils and fats containing a high concentration of arachidonic acid obtained by a microbiological method as disclosed in JP-A-63-44891 are suitable for that purpose, and compositions containing such oils and fats are preferred. It has been found that the amount of prostaglandin is increased in the liver damaged by ethanol, ethanol, drugs, etc., and that it is useful for the prevention and treatment of liver damage, and the present invention has been completed.
【０００４】[0004]
【課題を解決するための手段】すなわち、本発明は、ア
ラキドン酸含有量が２重量％以上の油脂を必須成分とし
てなることを特徴とする肝障害の予防または治療用組成
物を提供するものである。Means for Solving the Problems That is, the present invention provides a composition for preventing or treating liver damage, which comprises an oil and fat having an arachidonic acid content of 2% by weight or more as an essential component. is there.
【０００５】天然に存在する油脂においては、アラキド
ン酸含有量が２重量％に達するものは見当たらず、本発
明においては、アラキドン酸生産能を有する微生物から
得られる、アラキドン酸濃度が２重量％以上、好ましく
は、１０〜９９重量％、さらに好ましくは、２０〜９９
重量％の油脂を必須成分として配合する。アラキドン酸
の量が少なすぎると、その配合効果が期待できないの
で、かかる油脂は本発明の組成物中のアラキドン酸の含
有量が、組成物全量に対して２重量％以上、好ましく
は、１０重量％以上となるように配合する。No naturally occurring oil or fat has an arachidonic acid content of up to 2% by weight. In the present invention, the concentration of arachidonic acid obtained from a microorganism capable of producing arachidonic acid is 2% by weight or more. %, Preferably 10 to 99% by weight, more preferably 20 to 99
A fat and oil of weight% is added as an essential component. If the amount of arachidonic acid is too small, the compounding effect cannot be expected, so that the content of arachidonic acid in the composition of the present invention is 2% by weight or more, preferably 10% by weight, with respect to the total amount of the composition. It is blended so as to be at least%.
【０００６】このような、比較的高濃度のアラキドン酸
を含有する油脂は、例えば、前記した特開昭６３−４４
８９１号に開示される方法に従い、モルティエレラ（Mo
rtierella alpinal) 属に属するアラキドン酸生産菌
を、炭素源としてグルコース、窒素源として酵母エキス
を用い、好ましくは大豆油の存在下で培養し、アラキド
ン酸を含有画分を抽出、濃縮することにより、得ること
ができる。Such oils and fats containing a relatively high concentration of arachidonic acid are disclosed in, for example, the above-mentioned JP-A-63-44.
According to the method disclosed in No. 891, Mortierella (Mo
rtierella alpinal) arachidonic acid-producing bacterium belonging to the genus, glucose as a carbon source, using yeast extract as a nitrogen source, preferably cultivated in the presence of soybean oil, by extracting and concentrating a fraction containing arachidonic acid, Obtainable.
【０００７】本発明の組成物は、かかる比較的高濃度の
アラキドン酸を含有する油脂単独またはそれらの混合物
のみで構成してもよく、あるいは、このようなアラキド
ン酸含有油脂に加え、エイコサペンタエン酸(以下、Ｅ
ＰＡという)や、ドコサヘキサエン酸(以下、ＤＨＡとい
う)、γ−リノレン酸、リノール酸、これらの酸を含有
する油脂、例えば、大豆油、精製魚油等、ｄ−α−トコ
フェロール等のビタミン、食酢、食塩、甘味料、香辛料
等の調味料等を適宜含有させてもよい。The composition of the present invention may be constituted by oils and fats containing such a relatively high concentration of arachidonic acid alone or a mixture thereof, or in addition to such oils and fats containing arachidonic acid, eicosapentaenoic acid. (Hereafter, E
PA) and docosahexaenoic acid (hereinafter referred to as DHA), γ-linolenic acid, linoleic acid, oils and fats containing these acids, for example, soybean oil, purified fish oil, vitamins such as d-α-tocopherol, vinegar, Seasoning agents such as salt, sweeteners, spices and the like may be appropriately contained.
【０００８】特に、アラキドン酸と共に、ＥＰＡおよび
ＤＨＡを含有させることにより、アラキドン酸の体内吸
収が増進され、その肝障害の予防、治療効果がさらに向
上することが判明した。一般に、アラキドン酸に対する
重量比で、ＥＰＡを０.５〜３倍、ＤＨＡを０.５〜７倍
の割合で含有させると所望の向上効果が得られる。In particular, it has been found that the inclusion of EPA and DHA together with arachidonic acid enhances the absorption of arachidonic acid in the body and further improves the preventive and therapeutic effects on liver damage. Generally, a desired improvement effect can be obtained by incorporating EPA in a proportion of 0.5 to 3 times and DHA in a proportion of 0.5 to 7 times by weight of arachidonic acid.
【０００９】本発明の組成物は、常法により、油剤、エ
マルジョン、ソフトカプセル剤、ハードカプセル剤、錠
剤、顆粒剤、固形剤、チュアブル剤、ドレッシング類、
菓子類等の医薬や食品等の形態にすることができ、肝障
害の予防や治療の必要な人に対して経口的に摂取させる
ことができる。また、要すれば、可溶化等の公知の技術
に従って、非経口投与用の形態としてもよく、注射剤と
することもできる。また、人に限らず、ラット、ネズ
ミ、モルモット、サル、ヒヒ等の哺乳動物の肝障害の予
防、治療にも用いることができ、例えば、常法に従い、
飼料用の固体ないしは液体の添加剤とすることもでき
る。The composition of the present invention can be prepared by a conventional method using oils, emulsions, soft capsules, hard capsules, tablets, granules, solids, chewable agents, dressings,
It can be in the form of a medicine such as confectionery or food, and can be orally taken by a person in need of prevention or treatment of liver damage. In addition, if necessary, it may be in a form for parenteral administration or an injection, according to a known technique such as solubilization. Further, not only human, but also rat, rat, guinea pig, monkey, can be used for the prevention and treatment of liver damage in mammals such as baboons, for example, according to a conventional method,
It can also be used as a solid or liquid additive for feed.
【００１０】本発明の組成物は、通常、アラキドン酸の
１日の経口的摂取量が成人の場合、３００〜２０００ｍ
ｇ／日、好ましくは、４００〜１５００ｍｇ／日となる
ように与える。また、人以外の哺乳動物については、ア
ラキドン酸の１日の経口的摂取量が１〜５０ｍｇ／ｋ
ｇ、好ましくは、５〜３０ｍｇ／ｋｇとなるように与え
る。The composition of the present invention generally has a daily oral intake of arachidonic acid of 300 to 2000 m in adults.
g / day, preferably 400 to 1500 mg / day. For mammals other than humans, the daily oral intake of arachidonic acid is 1 to 50 mg / k.
g, preferably 5 to 30 mg / kg.
【００１１】[0011]
【実施例】以下に実施例および実験例を挙げて本発明を
さらに詳しく説明するが、本発明はこれに限定されるも
のではない。なお、実施例中の「％」は「重量％」を意
味する。 実施例１ 以下の処方により、常法に従い、ソフトカプセルを製造
した。 EXAMPLES The present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited thereto. In addition, "%" in an Example means "weight%." Example 1 Soft capsules were produced according to a conventional method according to the following formulation.
【００１２】実施例２ 以下の処方により、常法に従い、ドレッシングを製造し
た。 Example 2 A dressing was produced according to a conventional method according to the following formulation.
【００１３】実験例１ 動物実験 (実験方法)雄ラット（体重約２００ｇ）前後のものを使
用した。以下の成分からなる飼料を２０ｇ／日の量で経
口的に日与えた。 エタノールを空腹時に毎回チューブで３ｇ／ｋｇ／日投
入して肝障害を生じさせた。飼料にコーン油１０％加え
たのもと、コーン油９％およびアラキドン酸１％加えた
ものを食餌療法で動物に与えた。２週間後、動物を殺し
て肝臓を取り出し、コーン油１０％のみのものと、コー
ン油９％およびアラキドン酸１％のものとの差異を定
量、観察した。なお、コーン油はリノール酸を多く含
み、アラキドン酸を含まない。Experimental Example 1 Animal Experiment (Experimental Method) Male rats (body weight: about 200 g) were used. A diet consisting of the following components was orally given daily in an amount of 20 g / day. Ethanol was injected into the tube 3 g / kg / day every time on an empty stomach to cause liver damage. The animals were fed diet with 10% corn oil plus 9% corn oil and 1% arachidonic acid. Two weeks later, the animals were killed and the livers were taken out, and the difference between 10% corn oil alone and 9% corn oil and 1% arachidonic acid was quantified and observed. Corn oil contains a large amount of linoleic acid and does not contain arachidonic acid.
【００１４】肝臓中のリン脂質のアラキドン酸量および
６−ケト−ＰＧＦ1αの測定 (結果)表１に示すように、エタノールを与えてコーン油
だけを加えたものと、エタノールを与えずにコーン油だ
けを加えたものとでは、エタノールを与えた方がアラキ
ドン酸の量が低下している。このことより、エタノール
によってリノール酸からアラキドン酸の代謝が阻害され
ていることがわかる。しかし、アラキドン酸を加えるこ
とによって、アラキドン酸不足を補うことができる。ま
た、プロスタグランジンの代謝産物である６−ケト−Ｐ
ＧＦ1αの量もアラキドン酸の量を反映しており、アラ
キドン酸量が少ないとプロスタグランジンの量も少なく
なっている。Measurement of arachidonic acid content of phospholipids in liver and 6-keto-PGF 1 α (results) As shown in Table 1, ethanol was added and corn oil alone was added, and ethanol was not added. When corn oil alone was added, the amount of arachidonic acid decreased when ethanol was added. This shows that ethanol inhibits the metabolism of arachidonic acid from linoleic acid. However, arachidonic acid deficiency can be supplemented by adding arachidonic acid. In addition, 6-keto-P which is a prostaglandin metabolite
The amount of GF 1 α also reflects the amount of arachidonic acid, and the lower the amount of arachidonic acid, the lower the amount of prostaglandin.
【００１５】[0015]
【表１】 [Table 1]
【００１６】[0016]
【発明の効果】本発明によれば、食品、医薬、飼料等と
して有用な肝障害の予防または治療用アラキドン酸含有
組成物が提供される。INDUSTRIAL APPLICABILITY According to the present invention, there is provided an arachidonic acid-containing composition useful for foods, medicines, feeds, etc. for the prevention or treatment of liver damage.
Claims (1)
脂を必須成分としてなることを特徴とする肝障害の予防
または治療用アラキドン酸含有組成物。1. An arachidonic acid-containing composition for preventing or treating liver damage, which comprises an oil and fat having an arachidonic acid content of 2% by weight or more as an essential component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33326791A JPH05163142A (en) | 1991-12-17 | 1991-12-17 | Arachidonic acid-containing composition for preventing and treating liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33326791A JPH05163142A (en) | 1991-12-17 | 1991-12-17 | Arachidonic acid-containing composition for preventing and treating liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05163142A true JPH05163142A (en) | 1993-06-29 |
Family
ID=18264197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33326791A Pending JPH05163142A (en) | 1991-12-17 | 1991-12-17 | Arachidonic acid-containing composition for preventing and treating liver disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05163142A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002002105A1 (en) * | 2000-06-29 | 2002-01-10 | Laxdale Limited | Therapeutic combinations of fatty acids |
| US6749849B2 (en) * | 1995-01-24 | 2004-06-15 | Martek Biosciences Corporation | Method for producing arachidonic acid |
| JP2009518332A (en) * | 2005-12-06 | 2009-05-07 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Unsaturated fatty acids as thrombin inhibitors |
| JP2010178745A (en) * | 1995-01-03 | 2010-08-19 | Martek Biosciences Corp | Arachidonic acid, production method thereof and use method thereof |
-
1991
- 1991-12-17 JP JP33326791A patent/JPH05163142A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010178745A (en) * | 1995-01-03 | 2010-08-19 | Martek Biosciences Corp | Arachidonic acid, production method thereof and use method thereof |
| US6749849B2 (en) * | 1995-01-24 | 2004-06-15 | Martek Biosciences Corporation | Method for producing arachidonic acid |
| US7195791B2 (en) | 1995-01-24 | 2007-03-27 | Martek Biosciences Corporation | Method for production of archidonic acid |
| US7601523B2 (en) | 1995-01-24 | 2009-10-13 | Martek Biosciences Corporation | Method for production of arachidonic acid |
| US7666657B2 (en) | 1995-01-24 | 2010-02-23 | Martek Biosciences, Inc. | Method for production of arachidonic acid |
| US7736885B2 (en) | 1995-01-24 | 2010-06-15 | Martek Biosciences, Inc. | Method for production of arachidonic acid |
| WO2002002105A1 (en) * | 2000-06-29 | 2002-01-10 | Laxdale Limited | Therapeutic combinations of fatty acids |
| JP2009518332A (en) * | 2005-12-06 | 2009-05-07 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Unsaturated fatty acids as thrombin inhibitors |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6479544B1 (en) | Therapeutic combinations of fatty acids | |
| JP2796838B2 (en) | Method of manufacturing a medicament for the treatment of schizophrenia and / or associated tardive movement disorder | |
| TW323230B (en) | ||
| EP0572159B1 (en) | Medicament for the treatment of vulvar dystrophy or vaginal dryness | |
| AU2001274276A1 (en) | Therapeutic combinations of fatty acids | |
| US20040157932A1 (en) | Supplements and foods comprising oleylethanolamide | |
| JPH10504016A (en) | Enteric formulations for the treatment of inflammation and infections comprising saponins, preferably in combination with other compounds | |
| JPH10508189A (en) | Method for reducing animal body fat by administering conjugated linoleic acid | |
| US20140088047A1 (en) | Use of long chain polyunsaturated fatty acid derivatives to treat sickle cell disease | |
| JPH0788301B2 (en) | Composition for treating or preventing memory loss | |
| JPS6377817A (en) | Therapeutical composition, manufacture and therapy thereby | |
| JP2574153B2 (en) | Drugs for cancer treatment | |
| EP0769917B2 (en) | Nervonic acid compositions | |
| JP2677949B2 (en) | Health food containing arachidonic acid | |
| JPH10500937A (en) | Anti-inflammatory and protective effects of sesaminic lignans | |
| JPH05163142A (en) | Arachidonic acid-containing composition for preventing and treating liver disease | |
| JPH06271464A (en) | Arachidonic acid-containing composition for prevention or improvement of alimentary disorder | |
| JP4721642B2 (en) | Preventive or ameliorating agent for liver diseases associated with liver damage | |
| JP2941787B2 (en) | Pharmaceutical composition and health food containing polyunsaturated fatty acid | |
| JP3947322B2 (en) | Pharmaceutical composition and health food containing polyunsaturated fatty acid | |
| JP5759663B2 (en) | Skin barrier function improver, etc. | |
| JPH05310567A (en) | Agent for lowering concentration of serum triglyceride | |
| JP2005225863A (en) | Lipase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20010220 |